Nature Medicine
Oral small-molecule GLP-1 receptor agonist safiglipron in early type 2 diabetes: a randomized, double-blind, placebo-controlled trial
Randomised trial in 284 peopleType 2 diabetes
Papers by Zhaoyang Zeng
4 results
- Science China Life Sciences
Burden of cancer in China from 1990 to 2023 and projections to 2050
Computational studyCancer - ADA Scientific Sessions 2026 Abstract
Benefits of HR17031 vs. Insulin Glargine (iGlar) in Patients (pts) with Type 2 Diabetes (T2D) Uncontrolled on Metformin (Met) with/without One Other Oral Antidiabetic Drug (OAD)
Trial in peopleInterventions